Reading the tape
NASDAQ: PRAX
Praxis Precision Medicines, Inc.
Healthcare · Biotechnology
Market Cap
$6.74B
52w High
$356.00
52w Low
$34.89
P/E
-23.66
Volume
466.70K
Outstanding Shares
21.14M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 747.05%Revenue (TTM): -100%FCF (TTM): -89.75%
What changed
The stock rose 747.05% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow declined 89.75% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive move in revenue — currently down 100% — would be the clearest signal to resolve the ambiguity.
Company profile
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance.
CEOMarcio Silva De'Souza
SectorHealthcare
IndustryBiotechnology
Employees116
IPO dateOct 16, 2020
Valuation
Forward P/E—
EV/EBITDA-20.70
Enterprise value$6.28B
Stock splits
Nov 29, 2023↓ Reverse
Every 15 shares became 1
Profitability & growth
Revenue growth-100%
Gross margin0%
Operating margin0%
ROE-34.54%▲15.85%vs FY2024
Analyst consensus
RatingBuy
Target price$544.40▲70.75%
12
Buy
3
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 1, 2026
Q2 FY26 · EPS est -$3.58 · Revenue est $100K
View